

2. Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol*. 2014; 65: 69.

3. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. *Eur Urol Suppl*. 2008; 7: 667.

4. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. *Eur Urol*. 2003; 44: 429.

5. Marques M, Vazquez D, Sousa S, et al. Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review. *Pulmonology*. 2020; 26(6): 346–352.

19.–20. 5. 2023

8. ROČNÍK

KNOU

KOMPLEXNÍ
NOVINKY 2023
V ONKOUROLOGII

Hotel Vienna House Andel's, Stroupežnického 21, Praha 5

Registrace, odborný program a další informace: www.knou.cz

Pořadatel a organizátor  4Education